VYNE Therapeutics Reports Second Quarter 2022 Financial Results
VYNE Therapeutics Inc. (VYNE) reported its financial results for the second quarter and first half of 2022. For Q2, the company posted a net loss of $8.5 million, significantly down from $19.9 million in Q2 2021. Revenues fell to $0.1 million compared to $0.3 million the previous year, primarily from royalty revenue. Research and development expenses decreased by 18.6% to $4.1 million, while selling, general, and administrative expenses declined by 10.1% to $4.3 million. VYNE has $42.8 million in cash reserves, expected to fund operations into Q3 2023.
- Net loss decreased to $8.5 million in Q2 2022 from $19.9 million in Q2 2021.
- Research and development expenses fell 18.6% to $4.1 million.
- Selling, general and administrative expenses reduced by 10.1% to $4.3 million.
- Cash and cash equivalents of $42.8 million expected to fund operations until Q3 2023.
- Revenues dropped to $0.1 million in Q2 2022, down from $0.3 million in Q2 2021.
- The company will not generate revenue from AMZEEQ or ZILXI due to the MST Franchise divestiture.
BRIDGEWATER, N.J., Aug. 12, 2022 (GLOBE NEWSWIRE) -- VYNE Therapeutics Inc. (Nasdaq: VYNE) (“VYNE” or the “Company”), a biopharmaceutical company developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions, today announced financial results for the three and six months ended June 30, 2022.
"We believe our BET inhibitor platform holds unique and significant potential to address several immuno-inflammatory diseases, and we look forward to communicating our future plans following our review of our pipeline and prioritization of activities," said David Domzalski, President and Chief Executive Officer of VYNE.
| Financial Performance (in thousands) | Three Months Ended June 30, | Six Months Ended June 30, | |||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Loss from continuing operations (GAAP) | $ | (8,235 | ) | $ | (10,685 | ) | $ | (16,929 | ) | $ | (21,561 | ) | |||
| Adjusted loss from continuing operations (non-GAAP)* | $ | (7,072 | ) | $ | (9,173 | ) | $ | (14,521 | ) | $ | (17,989 | ) | |||
| Net loss (GAAP) | $ | (8,476 | ) | $ | (19,924 | ) | $ | (3,806 | ) | $ | (40,474 | ) | |||
| Adjusted net loss (non-GAAP)* | $ | (7,313 | ) | $ | (18,023 | ) | $ | (1,750 | ) | $ | (36,131 | ) | |||
*See "Note Regarding the Use of Non-GAAP Financial Measures" elsewhere in this earnings release.
Liquidity and Capital Resources
As of June 30, 2022, VYNE had cash and cash equivalents of
VYNE currently anticipates that its cash and cash equivalents as of June 30, 2022 will be sufficient to fund its operations into the third quarter of 2023, without giving effect to any potential business development transactions or financing activities, including from the purchase agreement with Lincoln Park. See Note 1 to VYNE's unaudited interim condensed consolidated financial statements included in VYNE’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022 for additional discussion on liquidity and capital resources.
Financial Results for the Second Quarter Ended June 30, 2022
Due to the sale of the MST Franchise during the first quarter of 2022, the Company has classified the results of the MST Franchise as discontinued operations in its unaudited interim condensed consolidated statements of operations for all periods presented. See Note 3 to VYNE's unaudited interim condensed consolidated financial statements included in VYNE’s Quarterly Report on Form 10-Q for the second quarter ended June 30, 2022 for additional discussion on discontinued operations.
Revenues. Revenues for the three months ended June 30, 2022 were
VYNE divested the MST Franchise on January 12, 2022. As a result of the sale, the Company will not generate revenue from the sales of AMZEEQ or ZILXI following such date.
Research and development expenses. VYNE's research and development expenses for the three months ended June 30, 2022 were
Selling, general and administrative expenses. VYNE's selling, general and administrative expenses for the three months ended June 30, 2022 were
Net loss. Net loss for the three months ended June 30, 2022 was
About VYNE Therapeutics Inc.
VYNE’s mission is to improve the lives of patients by developing proprietary, innovative, and differentiated therapies for the treatment of immuno-inflammatory conditions. The Company’s unique and proprietary pipeline includes access to a library of bromodomain & extra-terminal (BET) domain inhibitors licensed from In4Derm Limited. The BET inhibitor platform includes lead programs VYN201 (pan-BETi) and VYN202 (selective-BETi) and access to a library of (BET) domain inhibitors for the potential treatment of immune-inflammatory conditions.
For more information about VYNE Therapeutics Inc. or its investigational products, visit www.vynetherapeutics.com. VYNE may use its website to comply with its disclosure obligations under Regulation FD. Therefore, investors should monitor VYNE’s website in addition to following its press releases, filings with the U.S. Securities and Exchange Commission, public conference calls, and webcasts.
In4Derm Limited is a spin-out of the University of Dundee’s School of Life Sciences.
Investor Relations:
John Fraunces
LifeSci Advisors, LLC
917-355-2395
jfraunces@lifesciadvisors.com
Tyler Zeronda
VYNE Therapeutics Inc.
908-458-9106
Tyler.Zeronda@VYNEtx.com
Cautionary Statement Regarding Forward-Looking Statements
This release includes forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including, but not limited to, statements regarding VYNE’s BET inhibitor platform, and other statements regarding the future expectations, plans and prospects of VYNE. All statements in this press release which are not historical facts are forward-looking statements. Any forward-looking statements are based on VYNE’s current knowledge and its present beliefs and expectations regarding possible future events and are subject to risks, uncertainties and assumptions that could cause actual results to differ materially and adversely from those set forth or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to: VYNE's review of its pipeline and prioritization of activities; VYNE’s ability to successfully develop its product candidates; the timing of commencement of future non-clinical studies and clinical trials; VYNE’s ability to enroll patients and successfully progress, complete, and receive favorable results in, clinical trials for its product candidates; VYNE’s ability to exercise its exclusive option with respect to an oral BET inhibitor candidate pursuant to the terms of the option agreement with In4Derm Limited; VYNE’s intentions and its ability to obtain additional funding, either through equity or debt financing transactions or collaboration arrangements; disruptions related to COVID-19 or another pandemic, epidemic or outbreak of a contagious disease, on the ability of VYNE’s suppliers to manufacture and provide materials for our product candidates, initiating and retaining patients in clinical trials, operating results, liquidity and financial condition; the regulatory approval process for VYNE’s product candidates, including any delay or failure in obtaining requisite approvals; the potential market size of treatments for any diseases and market adoption of products, if approved or cleared for commercial use, by physicians and patients; developments and projections relating to competitors and the pharmaceuticals industry, including competing drugs and therapies; the timing or likelihood of regulatory filings and approvals or clearances for product candidates; VYNE’s ability to comply with various regulations applicable to its business, including Nasdaq continued listing rules; VYNE’s ability to create intellectual property and the scope of protection it is able to establish and maintain for intellectual property rights covering its product candidates, including the projected terms of patent protection; risks that any of VYNE’s patents may be held to be narrowed, invalid or unenforceable or one or more of VYNE’s patent applications may not be granted and potential competitors may also seek to design around VYNE’s granted patents or patent applications; the timing, costs or results of litigation, including litigation to protect its intellectual property; VYNE’s ability to successfully challenge intellectual property claimed by others; estimates of VYNE’s expenses, capital requirements, its needs for additional financing and its ability to obtain additional capital on acceptable terms or at all; VYNE’s ability to attract and retain key scientific or management personnel; VYNE’s defense of any litigation that may be initiated against it; VYNE’s expectations regarding licensing, business transactions and strategic operations; VYNE’s future financial performance and liquidity; and volatility in VYNE’s stock price may result in rapid and substantial increases or decreases in the stock price that may or may not be related to the company’s operating performance or prospects. For a discussion of other risks and uncertainties, and other important factors, any of which could cause VYNE’s actual results to differ from those contained in the forward-looking statements, see the section titled “Risk Factors” in VYNE’s Annual Report on Form 10-K for the year ended December 31, 2021 and VYNE’s Quarterly Report on Form 10-Q for the quarter ended June 30, 2022, as well as discussions of potential risks, uncertainties, and other important factors in VYNE’s subsequent filings with the U.S. Securities and Exchange Commission. Although VYNE believes these forward-looking statements are reasonable, they speak only as of the date of this announcement and VYNE undertakes no obligation to update publicly such forward-looking statements to reflect subsequent events or circumstances, except as otherwise required by law. Given these risks and uncertainties, you should not rely upon forward-looking statements as predictions of future events.
VYNE THERAPEUTICS INC.
CONDENSED CONSOLIDATED BALANCE SHEETS
(U.S. dollars in thousands, except per share data)
(Unaudited)
| June 30, | December 31, | ||||||
| 2022 | 2021 | ||||||
| Assets | |||||||
| Current Assets: | |||||||
| Cash and cash equivalents | $ | 42,814 | $ | 42,250 | |||
| Restricted cash | — | 605 | |||||
| Trade receivables, net of allowances | 304 | 7,583 | |||||
| Amount due from sale of MST Franchise | 5,000 | — | |||||
| Prepaid expenses and other assets | 3,772 | 4,565 | |||||
| Operating lease right of use assets | 30 | 338 | |||||
| Discontinued operations - current assets | — | 7,845 | |||||
| Total Current Assets | 51,920 | 63,186 | |||||
| Property and equipment, net | 298 | 354 | |||||
| Non-current prepaid expenses and other assets | 2,974 | 3,506 | |||||
| Total Assets | $ | 55,192 | $ | 67,046 | |||
| Liabilities and stockholders’ equity | |||||||
| Current Liabilities: | |||||||
| Trade payables | $ | 1,431 | $ | 6,510 | |||
| Accrued expenses | 3,514 | 8,593 | |||||
| Employee related obligations | 1,603 | 2,752 | |||||
| Liability for employee severance benefits | 256 | 206 | |||||
| Operating lease liabilities | 31 | 349 | |||||
| Total Liabilities | 6,835 | 18,410 | |||||
| Commitments and Contingencies | |||||||
| Stockholders' Equity: | |||||||
| Preferred stock: December 31, 2021; no shares issued and outstanding at June 30, 2022 and December 31, 2021 | — | — | |||||
| Common stock: and December 31, 2021; 58,005,616 and 53,577,744 shares issued and outstanding at June 30, 2022 and December 31, 2021, respectively | 6 | 5 | |||||
| Additional paid-in capital | 691,682 | 688,156 | |||||
| Accumulated deficit | (643,331 | ) | (639,525 | ) | |||
| Total Stockholders' Equity | 48,357 | 48,636 | |||||
| Total Liabilities and Stockholders’ Equity | $ | 55,192 | $ | 67,046 | |||
VYNE THERAPEUTICS INC.
CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(U.S. dollars in thousands, except per share data)
(Unaudited)
| Three months ended June 30, | Six months ended June 30, | ||||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||||
| Revenues | |||||||||||||||
| Royalty revenues | 126 | 295 | 304 | 525 | |||||||||||
| Total Revenues | 126 | 295 | 304 | 525 | |||||||||||
| Operating expenses: | |||||||||||||||
| Research and development | 4,108 | 5,048 | 8,560 | 9,303 | |||||||||||
| Selling, general and administrative | 4,305 | 4,789 | 8,722 | 10,521 | |||||||||||
| Total operating expenses | 8,413 | 9,837 | 17,282 | 19,824 | |||||||||||
| Operating loss | (8,287 | ) | (9,542 | ) | (16,978 | ) | (19,299 | ) | |||||||
| Interest expense | — | (1,074 | ) | — | (2,136 | ) | |||||||||
| Other income (expense) | 52 | (69 | ) | 49 | (126 | ) | |||||||||
| Loss from continuing operations before income taxes | (8,235 | ) | (10,685 | ) | (16,929 | ) | (21,561 | ) | |||||||
| Income tax expense | — | — | — | — | |||||||||||
| Loss from continuing operations | (8,235 | ) | $ | (10,685 | ) | $ | (16,929 | ) | $ | (21,561 | ) | ||||
| Income (loss) from discontinued operations, net of income taxes | (241 | ) | $ | (9,239 | ) | $ | 13,123 | $ | (18,913 | ) | |||||
| Net loss | $ | (8,476 | ) | $ | (19,924 | ) | $ | (3,806 | ) | $ | (40,474 | ) | |||
| Loss per share from continuing operations, basic and diluted | $ | (0.14 | ) | $ | (0.21 | ) | $ | (0.30 | ) | $ | (0.43 | ) | |||
| Income (loss) per share from discontinued operations, basic and diluted | $ | (0.01 | ) | $ | (0.18 | ) | $ | 0.23 | $ | (0.38 | ) | ||||
| Loss per share basic and diluted | $ | (0.15 | ) | $ | (0.39 | ) | $ | (0.07 | ) | $ | (0.81 | ) | |||
| Weighted average shares outstanding, basic and diluted | 57,930 | 51,411 | 56,665 | 50,162 | |||||||||||
Non-GAAP Financial Measures
In evaluating the operating performance of its business, VYNE’s management considers adjusted net loss, adjusted net loss per share, adjusted loss from continuing operations, adjusted total operating expenses (including adjusted research and development expense and adjusted selling, general and administrative expense), adjusted operating loss and adjusted loss per share from continuing operations. These non-GAAP financial measures exclude stock-based compensation charges that are required by GAAP. The Company believes that these non-GAAP financial measures provide management, analysts, investors and other users of the Company’s financial information with meaningful supplemental information regarding the performance of the Company’s business by excluding the effect of certain non-cash expenses and items that VYNE believes may not be indicative of its operating performance, because they are either unusual and VYNE does not expect them to recur in the ordinary course of its business, or they are unrelated to the ongoing operation of the business in the ordinary course. These non-GAAP financial measures should not be considered superior to, but rather in addition to, other financial measures prepared by the Company in accordance with GAAP, including the period-to-period results. The Company’s method of determining these non-GAAP financial measures may be different from other companies’ methods and, therefore, may not be comparable to those used by other companies, and the Company does not recommend the sole use of these non-GAAP measures to assess its financial and earnings performance. For reasons noted above, the Company is presenting certain non-GAAP financial measures for the three and six months ended June 30, 2022 and 2021. The following tables reconcile non-GAAP financial measures presented in this press release.
The following tables provides detailed reconciliations of various other income statement data between GAAP and non-GAAP amounts for the three and six months ended June 30, 2022 and 2021 (in thousands, except per share data):
Reconciliation of net income (loss) to adjusted net income (loss) and net income (loss) per share to adjusted net income (loss) per share:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||
| Net loss (GAAP) | $ | (8,476 | ) | $ | (19,924 | ) | $ | (3,806 | ) | $ | (40,474 | ) | |
| Add-back: stock-based compensation expense | 1,163 | 1,901 | 2,056 | 4,343 | |||||||||
| Adjusted net loss (non-GAAP) | $ | (7,313 | ) | $ | (18,023 | ) | $ | (1,750 | ) | $ | (36,131 | ) | |
| Net loss per share, basic and diluted (GAAP) | $ | (0.15 | ) | $ | (0.39 | ) | $ | (0.07 | ) | $ | (0.81 | ) | |
| Add-back: stock-based compensation expense | 0.02 | 0.04 | 0.04 | 0.09 | |||||||||
| Adjusted net loss per share, basic and diluted (non-GAAP) | $ | (0.13 | ) | (0.35 | ) | $ | (0.03 | ) | $ | (0.72 | ) | ||
| Weighted average number of shares outstanding, basic and diluted | 57,930 | 51,411 | 56,665 | 50,162 | |||||||||
Reconciliation of loss from continuing operations to adjusted loss from continuing operations; research and development expense to adjusted research and development expense; selling, general and administrative expense to adjusted selling, general and administrative expense; total operating expense to adjusted total operating expense; operating loss to adjusted operating loss; and loss per share from continuing operations to adjusted loss per share from continuing operations:
| Three Months Ended June 30, | Six Months Ended June 30, | ||||||||||||
| 2022 | 2021 | 2022 | 2021 | ||||||||||
| Loss from continuing operations (GAAP) | $ | (8,235 | ) | $ | (10,685 | ) | $ | (16,929 | ) | $ | (21,561 | ) | |
| Add-back: stock-based compensation expense | 1,163 | 1,512 | 2,408 | 3,572 | |||||||||
| Adjusted loss from continuing operations (non-GAAP) | $ | (7,072 | ) | $ | (9,173 | ) | $ | (14,521 | ) | $ | (17,989 | ) | |
| Research and development expense (GAAP) | $ | 4,108 | $ | 5,048 | $ | 8,560 | $ | 9,303 | |||||
| Less: stock-based compensation expense | (393 | ) | (442 | ) | (622 | ) | (900 | ) | |||||
| Adjusted research and development expense (non-GAAP) | $ | 3,715 | $ | 4,606 | $ | 7,938 | $ | 8,403 | |||||
| Selling, general and administrative expense (GAAP) | $ | 4,305 | $ | 4,789 | $ | 8,722 | $ | 10,521 | |||||
| Less: stock-based compensation expense | (770 | ) | (1,070 | ) | (1,786 | ) | (2,672 | ) | |||||
| Adjusted selling, general and administrative expense (non-GAAP) | $ | 3,535 | $ | 3,719 | $ | 6,936 | $ | 7,849 | |||||
| Total operating expenses (GAAP) | $ | 8,413 | $ | 9,837 | $ | 17,282 | $ | 19,824 | |||||
| Less: stock-based compensation expense | (1,163 | ) | (1,512 | ) | (2,408 | ) | (3,572 | ) | |||||
| Adjusted total operating expenses (non-GAAP) | $ | 7,250 | $ | 8,325 | $ | 14,874 | $ | 16,252 | |||||
| Operating loss (GAAP) | $ | (8,287 | ) | $ | (9,542 | ) | $ | (16,978 | ) | $ | (19,299 | ) | |
| Add back: stock-based compensation expense | 1,163 | 1,512 | 2,408 | 3,572 | |||||||||
| Adjusted operating loss (non-GAAP) | $ | (7,124 | ) | $ | (8,030 | ) | $ | (14,570 | ) | $ | (15,727 | ) | |
| Loss per share from continuing operations, basic and diluted (GAAP) | $ | (0.14 | ) | $ | (0.21 | ) | $ | (0.30 | ) | (0.43 | ) | ||
| Add back: stock-based compensation expense | 0.02 | 0.03 | 0.04 | 0.07 | |||||||||
| Adjusted loss per share from continuing operations, basic and diluted (non-GAAP) | $ | (0.12 | ) | $ | (0.18 | ) | $ | (0.26 | ) | $ | (0.36 | ) | |
| Weighted average number of shares outstanding - basic and diluted | 57,930 | 51,411 | 56,665 | 50,162 | |||||||||
FAQ
What were VYNE's Q2 2022 financial results?
How much cash does VYNE have as of June 30, 2022?
What caused the revenue decline for VYNE in Q2 2022?
What steps is VYNE taking regarding its pipeline?
What are VYNE's future funding expectations?
